ArticleHaematologica2021

Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO).

Jesus San-Miguel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.